Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

Rhea-AI Summary

Vallon Pharmaceuticals (NASDAQ: VLON) will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15, 2021, at 8:30 am ET. David Baker, President & CEO, will lead the presentation, which is part of Vallon's commitment to developing novel drugs aimed at preventing abuse in the treatment of CNS disorders. Following the presentation, management will participate in virtual one-on-one meetings with qualified investors. The event will be archived for 90 days on the company's website.

- Live video webcast presentation on Monday, November 15^th at 8:30 am ET

PHILADELPHIA, PA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that David Baker, President & Chief Executive Officer will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on Monday, November 15, 2021 at 8:30 am ET.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The video webcast presentation will be accessible on the conference website and on the Events page of the Investors section of the Company’s website (www.vallon-pharma.com) and will be archived for 90 days following the event.

About Vallon Pharmaceuticals, Inc.

Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with CNS disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter.

References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
vallon@jtcir.com

FAQ

When is Vallon Pharmaceuticals' presentation at the H.C. Wainwright conference?

Vallon Pharmaceuticals will present on November 15, 2021, at 8:30 am ET.

Who is presenting for Vallon Pharmaceuticals at the conference?

David Baker, President & CEO, will be the presenter at the H.C. Wainwright conference.

How can I access Vallon Pharmaceuticals' webcast presentation?

The webcast will be accessible on the conference website and the Investors section of Vallon's website.

What is the focus of Vallon Pharmaceuticals?

Vallon Pharmaceuticals focuses on developing novel drugs to deter abuse in CNS disorder treatments.

What is Vallon's lead investigational product candidate?

Vallon's lead product candidate is ADAIR, an abuse deterrent formulation of amphetamine for ADHD and narcolepsy.